Subscribe

Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

HKD3.04 +0.15 (+5.19%)
CN HKSE Healthcare Biotechnology
Address Building 4
Shanghai, CN
CEO Li Wang
Website bio-heart.com
IPO 2021-12-23
ISIN CNE100004JH3

Explore sections of this company profile

Description

Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD3.04 +0.15 (+5.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
619.0K
Beta
0.09
Float Shares
215.44M
Free Float %
91.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.13% -11.18% -25.06% -42.15% -56.23% -47.84% +16.15% -36.95% -84.98% -84.98% -84.98%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
3.04
DCF (Unlevered) 6.87 +125.9%
DCF (Levered) 3.02 -0.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-01 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.80
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    —
  • ✗
    EPS growth Biotechnology: +29.7%
    +22.2% Q4'25: +50.0% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -131.7% Q4'25: -275.5% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -159.6% Q4'25: -209.6% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -18.6% Q4'25: -32.1% (vs Q4'23)
  • ✓
    Share dilution Biotechnology: -3.4%
    +0.0% ★ Q4'25: -3.2% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.24× Q4'25: -0.08× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.13) × ERP
WACC = 98% × Ke + 2% × Kd (66.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 6.88 Current price: 3.04
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
—
est: 27.83M (-100.0%)
—
est: 206.22M (-100.0%)
—
est: 530.81M (-100.0%)
43.77M
est: 1.06B (-95.9%)
2.14B
2.14B – 2.14B
+101.6% YoY
407.78M
407.78M – 407.78M
-81.0% YoY
EBITDA
-237.34M
-148.21M
-44.54M
est: 318.48M (-114.0%)
-52.13M
est: 638.13M (-108.2%)
1.29B
1.29B – 1.29B
+101.6% YoY
244.67M
244.67M – 244.67M
-81.0% YoY
EBIT
-252.20M
-164.62M
-61.04M
est: 318.48M (-119.2%)
-69.84M
est: 638.13M (-110.9%)
1.29B
1.29B – 1.29B
+101.6% YoY
244.67M
244.67M – 244.67M
-81.0% YoY
Net Income
-237.50M
est: -326.65M (+27.3%)
-194.36M
est: -249.78M (+22.2%)
-87.94M
-68.24M
est: -41.54M (-64.3%)
-54.66M
-54.66M – -54.66M
-31.6% YoY
-28.42M
-28.42M – -28.42M
+48.0% YoY
SGA
100.29M
16.09M
19.74M
est: 452.60M (-95.6%)
11.53M
est: 906.87M (-98.7%)
1.83B
1.83B – 1.83B
+101.6% YoY
347.71M
347.71M – 347.71M
-81.0% YoY
EPS
-0.98
est: -1.34 (+27.0%)
-0.72
est: -1.03 (+29.8%)
-0.36
-0.28
est: -0.17 (-64.1%)
-0.22
-0.22 – -0.22
-31.6% YoY
-0.12
-0.12 – -0.12
+48.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-28 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-27 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-26 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-22 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-21 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-20 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-19 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-18 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-15 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-14 C+ 2/5 4/5 1/5 1/5 3/5 1/5 2/5
2026-05-13 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-05-12 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-05-11 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-05-08 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-07 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-05-06 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-05 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-04 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-04-30 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-04-29 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-04-28 C+ 2/5 4/5 1/5 1/5 3/5 1/5 3/5
2026-04-27 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-24 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-23 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-22 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-21 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-20 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-1.11M
Shares Outstanding
235.70M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Yunqing Wang Chief Financial Officer, Joint Company Secretary & Executive Director 1M male
Peili Wang Financial Manager & Executive Director 876.0K female
Li Wang Executive Chairman of the Board, Chief Executive Officer & GM 818.2K male
Tao Cai Chairperson of the Board of Supervisors & Head of Technology 187.2K male
Bradley Stewart Hubbard Chief Medical Officer — —
Siu Ying Kwok Joint Company Secretary — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology